Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis |
| |
| Authors: | Abraham Fisher Rachel Brandeis Rachel Haring Naomi Eshhar Eliahu Heldman Yishai Karton Orli Eisenberg Haim Meshulam Daniele Marciano Nira Bar-Ner Zipora Pittel |
| |
| Affiliation: | 1. Addis Ababa University, Ethiopian Institute of Water Resources, Ethiopia;2. Haramaya University, College of Health and Medical Sciences, Harar, Ethiopia;3. University of Connecticut, Department of Civil and Environmental Engineering, Storrs, USA;4. University of California, Department of Epidemiology and Biostatistics, San Francisco, USA;1. Department of Chemistry & Biochemistry, South Dakota State University, Brookings, SD 57007, United States;2. Department of Chemistry & Biochemistry, North Dakota State University, Fargo, ND 58105, United States;3. Division of Basic & Translational Research, Department of Surgery, University of Minnesota, 420 Delaware St SE. MMC 195, Minneapolis, MN 55455, United States;1. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King''s College London, London SE5 8AF, United Kingdom;2. Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom;1. Department of Psychology, Temple University, United States;2. Neuroscience Program, Temple University, United States;1. Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Avda. Vicent Andrés Estellés s/n., 46100 Burjassot, Spain;2. Department of Cellular Biology, Functional Biology and Physical Anthropology, University of Valencia, Avda. Vicent Andrés Estellés s/n., 46100 Burjassot, Spain |
| |
| Abstract: | M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.RésuméLes agonistes sélectifs de type M1 appartenant à la série AF (par exemple AF102B, AF150(S)) activent de manière sélective certaines routes de transduction du signal via les récepteurs muscariniques de type m1, augmentent la sécrétion de la protéine amyloide par les cellules transfectées et les cultures primaires de cellules, produisent des effets neurotrophiques et se montrent bénéfiques pour une variété de modèles animaux de la maladie d'Alzheimer. De tels agonistes peuvent être efficaces pour traiter et guérir la maladie d'Alzheimer. |
| |
| Keywords: | AF series m1 agonists Alzheimer's disease |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
